The Pharmacy Times® human immunodeficiency virus (HIV) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Learn how retail or specialty pharmacy distribution can affect access to these important drugs.
Following the global impact of COVID-19 on the health care system in 2020, there have been some clear changes in HIV care in the United States.
Successfully implementing HIV and hepatitis C testing at drug detoxification centers could help identify and link patients to care, but would require that the test results are available to nearby health care facilities.
Although antiretroviral therapy is an important option for patients with HIV, the viral reservoir has been a major obstacle for researchers looking to effectively cure the disease.
According to results from a recent study, a functional cure for HIV may lie in identifying the viral reservoirs in which HIV places copies of its viral genetic material into cell genomes.
According to the study authors, with a higher antigen valency, antibodies have more sites to latch onto; however, including a higher antigen valency in a vaccine does not mean it will work better.
Antiretroviral therapy’s limitations lead to new efforts to treat the virus by neutralizing antibodies.
Despite, antiretroviral therapy, HIV can hide in blood and tissue.
Fingolimod (Gilenya), which is approved by the FDA to treat multiple sclerosis flare-ups, may also block HIV and reduce the latent reservoir.
A new study found that it’s safe for patients with HIV to receive HIV-positive kidneys.
As patients return to their routines of returning to pharmacies and the inevitable discussions about COVID-19 begin, it may be a good time to discuss the range of tests that the CDC recommends.
Globally, dolutegravir is expected to be a part of treatment for approximately 15 million people living with HIV by 2021.